Annexon, Inc. Common Stock
ANNXAnnexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. It specializes in targeting the complement system to address conditions such as Alzheimer’s disease, multiple sclerosis, and other immune-related disorders. The company's approach involves creating monoclonal antibodies that modulate the immune response to prevent cellular damage.
Company News
Annexon, a biopharmaceutical company, granted a stock option to a new non-executive employee for 19,000 shares with a 4-year vesting schedule and an exercise price of $4.91 per share.
Annexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.
Annexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.
The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.
Annexon announced presentations at the 2025 PNS Meeting highlighting improved outcomes with its investigational therapy tanruprubart for the treatment of Guillain-Barré Syndrome (GBS), a rare autoimmune disease with no approved treatments.
